Diffuse Hemispheric Glioma, H3 G34-Mutant Clinical Trials

3 recruiting

Diffuse Hemispheric Glioma, H3 G34-Mutant Trials at a Glance

5 actively recruiting trials for diffuse hemispheric glioma, h3 g34-mutant are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Columbus, Sutton, and Ann Arbor. Lead sponsors running diffuse hemispheric glioma, h3 g34-mutant studies include Institute of Cancer Research, United Kingdom, National Cancer Institute (NCI), and Nationwide Children's Hospital.

Browse diffuse hemispheric glioma, h3 g34-mutant trials by phase

Treatments under study

About Diffuse Hemispheric Glioma, H3 G34-Mutant Clinical Trials

Looking for clinical trials for Diffuse Hemispheric Glioma, H3 G34-Mutant? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diffuse Hemispheric Glioma, H3 G34-Mutant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diffuse Hemispheric Glioma, H3 G34-Mutant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

Resectable Brain NeoplasmRecurrent Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Malignant Brain Neoplasm
University of Michigan Rogel Cancer Center11 enrolled1 locationNCT06914479
Recruiting
Phase 1Phase 2

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom182 enrolled3 locationsNCT06630260
Recruiting
Phase 1

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom12 enrolled2 locationsNCT06632236